Loading data for EWTX — first visit, this takes a few seconds.

알림

Edgewise Therapeutics Inc... (EWTX)

NasdaqGS: EWTX · 실시간 가격 · USD

43.29

-3.15 (-6.78%)

종가 기준: Aug 21, 2026, 8:00 PM

44.18

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-6.78% (1D)

데이터 없음

매수호가	32.84
시가총액	4.8B
매출 (ttm)	n/a
순이익 (ttm)	-197.22M
	0.33
	-1.85
	n/a
	-24.33
P/B (ttm)	10.63
P/S (ttm)	n/a
실적 발표일	Nov 5, 2026

매도호가	55.44
거래량	787,834
평균 거래량 (20일)	1,443,024
시가	45.76
전일 종가	46.44
일중 범위	43.08 - 45.76
52주 범위	13.64 - 48.40
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

EWTX 소개

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatm...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 26, 2021

직원 수 127

상장 거래소 NasdaqGS

티커 EWTX

웹사이트 https://edgewisetx.com

전체 기업 정보

재무 실적

2025년 Edgewise Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -167.79M로, 25.4% 증가했습니다.

재무제표

어닝 서프라이즈

Edgewise Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.53 예상치 하회 -0.06, 및 -55.88% 전년 대비 감소.

다음 실적 발표

Edgewise Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Simply Wall St.

Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?

How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past d...

1개월 전 · Zacks

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.

1개월 전 · Pharmaceutical Technology

Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

1개월 전 · Insider Monkey

Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?

Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on EWTX. Edgewise Therap...

2개월 전 · Insider Monkey

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks. TheFly reported on...

2 페이지 중 1

Edgewise Therapeutics Inc... (EWTX)